Evidence map›Paper›PMID 40251389›Full record

ArticleEJNMMI research2025

Evaluation of early chemotherapy response by combining static- and dynamic [

Heidi Espedal, Jenny M Lyngstad, Hege F Berg, Marta E Hjelmeland, Kristine E Fasmer, Camilla Krakstad, Ingfrid S Haldorsen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Heidi EspedalDepartment of Clinical Medicine, University of Bergen, Bergen, Norway. heidi.espedal@uib.no.ORCID http://orcid.org/0000-0002-0190-8999
Jenny M LyngstadDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Hege F BergCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Marta E HjelmelandCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Kristine E FasmerMohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Camilla KrakstadCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Ingfrid S HaldorsenDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe combination of carboplatin and paclitaxel is the standard chemotherapy for treatment of high-risk and recurrent endometrial cancer. Evaluation of treatment response by diagnostic imaging is routinely carried out months after start of treatment, and is based on changes in tumor size or appearance of new metastases. The aim of this study was to evaluate early chemotherapeutic response in two subcutaneous endometrial cancer mouse models generated from patient-derived organoids using static- and dynamic [

resultsAt endpoint, tumor volumes at T2w-MRI (vMRI) were lower in the treatment groups in both models (p ≤ 0.029). The tumor metabolic rate (MR

conclusionsMultimodal imaging is feasible for evaluation of early signs of treatment response in preclinical subcutaneous endometrial cancer models. The novel MR

Indexed as

ChemotherapyDiffusion-weighted MRIDynamic PETEndometrial cancerMetabolic rate of glucoseOrganoid modelsPreclinical imagingTreatment response

Identifiers

PMID40251389
PMCPMC12008091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.